Ascendis Pharma A/S (NASDAQ:ASND) Price Target Raised to $225.00
Ascendis Pharma A/S (NASDAQ:ASND – Free Report) had its price objective raised by The Goldman Sachs Group from $200.00 to $225.00 in a research note issued to investors on Thursday,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock. Several other equities analysts also recently issued reports on the stock. TD Cowen […]
Ascendis Pharma A/S (NASDAQ:ASND – Free Report) had its price objective raised by The Goldman Sachs Group from $200.00 to $225.00 in a research note issued to investors on Thursday,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock. Several other equities analysts also recently issued reports on the stock. TD Cowen […]
